How India Exports Ramipril to the World

Ramipril, an angiotensin-converting enzyme (ACE) inhibitor, has been widely approved in the United States through Abbreviated New Drug Applications (ANDAs). The FDA's Orange Book lists multiple approved ANDAs for ramipril, indicating a well-established generic market. Notably, the brand-name version, Altace, received its initial FDA approval on January 28, 1991, but all formulations have since been discontinued.

The absence of active import alerts or significant regulatory actions against ramipril underscores its compliance with FDA standards. Given that 177 Indian exporters have been active in the ramipril market, it is imperative for these entities to maintain rigorous adherence to FDA regulations to ensure continued market access.

In the European Union, ramipril is subject to the European Medicines Agency's (EMA) marketing authorization process. A notable development occurred in December 2022 when the EMA recommended the authorization of Rambis, a combination of ramipril and bisoprolol, highlighting the agency's ongoing evaluation of ramipril-containing products. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees ramipril's approval and monitoring. Recently, in March 2026, the MHRA issued a Class 2 Medicines Recall for a batch of Ramipril 5 mg Capsules due to a potential manufacturing error, emphasizing the importance of stringent quality control measures. (gov.uk)

Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for all manufacturers supplying ramipril to these markets, ensuring product quality and patient safety.

Ramipril is included in the World Health Organization's (WHO) Model List of Essential Medicines, with the 24th edition published in September 2025. (who.int) This inclusion underscores its critical role in managing cardiovascular conditions globally. Manufacturers must ensure that ramipril formulations meet the standards set forth in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to guarantee consistent quality across different markets.

In India, ramipril is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. For instance, the ceiling price for ramipril was revised in July 2025, reflecting the government's commitment to making essential medicines accessible. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) before exporting ramipril, ensuring compliance with national regulations.

The primary patent for ramipril expired on October 29, 2008. Prior to this, in September 2007, the United States Court of Appeals for the Federal Circuit invalidated Aventis's patent on ramipril due to "obviousness," paving the way for generic competition. Consequently, the market has seen a proliferation of generic versions, intensifying competition and influencing pricing strategies.

In March 2026, the UK's MHRA issued a Class 2 Medicines Recall for a batch of Ramipril 5 mg Capsules produced by Crescent Pharma Limited, citing potential manufacturing errors. (gov.uk) This incident highlights the critical importance of stringent quality control measures in pharmaceutical manufacturing.

In December 2022, the EMA recommended the authorization of Rambis, a combination of ramipril and bisoprolol, for use in the EU. (ema.europa.eu) This development reflects the agency's ongoing evaluation and approval of combination therapies involving ramipril, potentially expanding its therapeutic applications.

These developments underscore the dynamic nature of the pharmaceutical industry and the necessity for manufacturers and exporters to stay abreast of regulatory changes and quality standards to maintain market access and ensure patient safety.

India's pharmaceutical industry, including the production of Ramipril, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. This dependency exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade restrictions, and disruptions in Chinese manufacturing. Despite initiatives like the Production Linked Incentive (PLI) scheme launched in 2020 to bolster domestic API production, progress has been gradual. As of February 2024, the Indian pharmaceutical sector continues to import a significant portion of its APIs and KSMs from China, underscoring the persistent reliance on external sources.

Our proprietary trade data from 2022 to 2026 indicates that the top five exporters of Ramipril from India account for 63.7% of the total export value, with MYLAN LABORATORIES LIMITED leading at 18.9%. This high supplier concentration poses a risk, as disruptions affecting these key players could significantly impact the global supply of Ramipril. While the PLI scheme aims to diversify and strengthen the supplier base, its full impact on reducing single-source dependency remains to be seen.

Recent geopolitical events have further strained the supply chain. On February 28, 2026, military actions in the Middle East led to the effective closure of the Strait of Hormuz, a critical maritime chokepoint through which approximately 20% of the world's oil and significant volumes of other goods transit. This disruption has caused a sharp decline in maritime traffic, with tanker movements dropping by approximately 70% and over 150 ships anchoring outside the strait to avoid risks. The closure has led to increased shipping costs, extended transit times, and heightened risks of supply chain disruptions for pharmaceuticals exported from India. Additionally, the Red Sea and the Strait of Hormuz have become high-risk areas for commercial shipping due to escalating conflicts, further complicating logistics and increasing costs.

To address these risks, the following actionable steps are recommended:

• Diversify API and KSM Sources: Invest in developing alternative sources for APIs and KSMs, both domestically and from other countries, to reduce reliance on Chinese imports.

• Strengthen Supplier Base: Encourage the growth of smaller and mid-sized pharmaceutical exporters to decrease the high concentration among top suppliers.

• Enhance Supply Chain Visibility: Implement advanced tracking and monitoring systems to gain real-time insights into supply chain operations, enabling proactive responses to disruptions.

• Develop Contingency Plans: Establish comprehensive contingency strategies, including alternative shipping routes and logistics partners, to mitigate the impact of geopolitical and shipping disruptions.

• Engage in Policy Advocacy: Collaborate with industry associations and government bodies to advocate for policies that support supply chain resilience, such as incentives for domestic API production and infrastructure improvements.

RISK_LEVEL: HIGH